Relay Therapeutics Inc [NASDAQ: RLAY] price surged by 0.13 percent to reach at $0.01.
A sum of 6067984 shares traded at recent session while its average daily volume was at 1.92M shares. Relay Therapeutics Inc shares reached a high of $7.81 and dropped to a low of $7.42 until finishing in the latest session at $7.59.
The one-year RLAY stock forecast points to a potential upside of 44.03. The average equity rating for RLAY stock is currently 1.45, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Relay Therapeutics Inc [RLAY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RLAY shares is $13.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RLAY stock is a recommendation set at 1.45. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Relay Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 04, 2025. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Equal Weight. The new note on the price target was released on April 17, 2025, representing the official price target for Relay Therapeutics Inc stock. Previously, the target price had yet another raise from $10.60 to $16, while Jefferies kept a Buy rating on RLAY stock.
The Price to Book ratio for the last quarter was 2.16, with the Price to Cash per share for the same quarter was set at 3.44.
RLAY Stock Performance Analysis:
Relay Therapeutics Inc [RLAY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.07. With this latest performance, RLAY shares gained by 23.01% in over the last four-week period, additionally plugging by 127.25% over the last 6 months – not to mention a rise of 84.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RLAY stock in for the last two-week period is set at 56.95, with the RSI for the last a single of trading hit 0.46, and the three-weeks RSI is set at 0.45 for Relay Therapeutics Inc [RLAY]. The present Moving Average for the last 50 days of trading for this stock 6.80, while it was recorded at 7.70 for the last single week of trading, and 4.23 for the last 200 days.
Insight into Relay Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Relay Therapeutics Inc [RLAY] shares currently have an operating margin of -3914.38% and a Gross Margin at 48.64%. Relay Therapeutics Inc’s Net Margin is presently recorded at -3561.43%.
Relay Therapeutics Inc (RLAY) Capital Structure & Debt Analysis
According to recent financial data for Relay Therapeutics Inc. ( RLAY), the Return on Equity (ROE) stands at -41.14%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -37.20%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Relay Therapeutics Inc’s Return on Invested Capital (ROIC) is -46.69%, showcasing its effectiveness in deploying capital for earnings.
Relay Therapeutics Inc (RLAY) Efficiency & Liquidity Metrics
Based on Relay Therapeutics Inc’s (RLAY) latest financial statements, the Debt-to-Equity Ratio is 0.05%, indicating its reliance on debt financing relative to shareholder equity.
Relay Therapeutics Inc (RLAY) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Relay Therapeutics Inc. (RLAY) effectively leverages its workforce, generating an average of -$1140191.57 per employee. The company’s liquidity position is robust, with a Current Ratio of 19.14% and a Quick Ratio of 19.14%, indicating strong ability to cover short-term liabilities.
RLAY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RLAY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Relay Therapeutics Inc go to 10.08%.
Relay Therapeutics Inc [RLAY] Institutonal Ownership Details
There are presently around $98.11%, or 99.43%% of RLAY stock, in the hands of institutional investors. The top three institutional holders of RLAY stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 27.9 million shares, which is approximately 21.0093%. VANGUARD GROUP INC, holding 11.7 million shares of the stock with an approximate value of $$76.32 million in RLAY stocks shares; and VANGUARD GROUP INC, currently with $$68.74 million in RLAY stock with ownership which is approximately 7.9375%.
